Stock Evaluator: Natera, Inc. (NTRA)

Natera, Inc. NTRA

$267.76 -1.90 -0.70%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,331,408
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Commentary & Analysis


Financial Summary

Share Statistics NTRA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $38,619.5 $251.9 92%
Shares Out (Mil) 141.5 50.8 70%
Institutional Ownership 97.1% 92.0% 73%
Float (Mil) 139.0 40.5 68%
Beta 1.57 0.95 84%
Avg Daily Volume (000s) 905 447 69%
Price Change
(52-week)
98.5% 54.2% 92%
Growth NTRA Industry
Median
Percentile
(All Stocks)
Sales (5yr) 42.6% 14.0% 94%
Net Income (5yr) 1.9% (9.8%) 42%
EPS (5yr) 11.7% 16.3% 49
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 51.3% (15.6%) 94%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 13 14 14
Current EPS ($0.534) ($1.709) ($0.205)
Month Ago EPS ($0.521) ($1.679) ($0.208)
# Rev Up 0 1 1
# Rev Down 1 0 0
Three Months Ago EPS ($0.536) ($1.854) ($0.678)
Year/Year Chg (11.1%) 12.2% (214.2%)
Financials NTRA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $2,501 $39 64%
Net Income (TTM) (Mil) ($226) ($43) 6%
EPS (TTM) ($1.635) ($1.600) 17%
Operating Cash Flow (TTM) (Mil) $211 ($30) 60%
Net Cash Flow (TTM) (Mil) $114 $3 79%
Long-Term Debt (Q1) (Mil) $145 $5 47%
Enterprise Value (Q1) (Mil) $26,970 $182 87%
Valuation NTRA Industry
Median
Percentile
(All Stocks)
P/B 21.69 2.60 96%
P/E na 18.6 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.9 na
Ratios NTRA Industry
Median
Percentile
(All Stocks)
Gross Margin 65.1% 63.8% 77%
Net Margin (9.0%) (64.7%) 22%
ROA (10.4%) (49.7%) 25%
ROE (15.0%) (55.4%) 26%
Liabilities to Assets 32.1% 30.3% 23%
F-Score 5 3 51%

Natera, Inc. did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors